Literature DB >> 4076320

Alpha 1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11 epoxide in children with epilepsy.

M Contin, R Riva, F Albani, E Perucca, G Lamontanara, A Baruzzi.   

Abstract

The relationship between the serum protein binding of carbamazepine (CBZ) and carbamazepine-10,11 epoxide (CBZ-E) and the concentration of alpha 1-acid glycoprotein (AAG) and albumin (HSA) was examined in 39 CBZ-treated epileptic children aged 4 months to 12 years. A significant inverse correlation was found between the free fraction of both compounds and serum AAG, even though changes in AAG concentration explained only part of the variation in binding. No correlation was found between the free fraction of CBZ and CBZ-E and HSA, probably due to the small intersubject variation in HSA concentration. In vitro experiments showed that both CBZ and CBZ-E were bound to HSA and to a lesser extent to AAG. At equivalent HSA concentrations, the binding of CBZ and its metabolite increased proportionately with increasing AAG concentration within the range occurring clinically.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076320     DOI: 10.1007/BF00547424

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

2.  High alpha 1-acid glycoprotein concentrations in serum of epileptic children being treated with carbamazepine.

Authors:  R Riva; M Contin; F Albani; A Baruzzi; G Lamontanara
Journal:  Clin Chem       Date:  1985-01       Impact factor: 8.327

3.  Protein binding of carbamazepine in epileptic patients.

Authors:  L M Lawless; H J DeMonaco; L R Muido
Journal:  Neurology       Date:  1982-04       Impact factor: 9.910

4.  Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.

Authors:  R Riva; F Albani; G Ambrosetto; M Contin; P Cortelli; E Perucca; A Baruzzi
Journal:  Epilepsia       Date:  1984-08       Impact factor: 5.864

5.  Plasma proteins in patients on long-term antiepileptic treatment.

Authors:  R Olsson; L Hellner; G Lindstedt; P A Lundberg; A C Teger-Nilsson
Journal:  Clin Chem       Date:  1983-04       Impact factor: 8.327

6.  Laser nephelometry of orosomucoid in serum of newborns: reference intervals and relation to bacterial infections.

Authors:  J Bienvenu; L Sann; F Bienvenu; C Lahet; P Divry; J Cotte; M Bethenod
Journal:  Clin Chem       Date:  1981-05       Impact factor: 8.327

7.  Plasma protein binding of carbamazepine.

Authors:  W D Hooper; D K Dubetz; F Bochner; L M Cotter; G A Smith; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

8.  Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant.

Authors:  M Wood; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

9.  Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Ambrosetto; G Procaccianti; M Santucci; A Baruzzi
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

10.  Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding.

Authors:  S A Bai; F P Abramson
Journal:  J Pharmacol Exp Ther       Date:  1982-09       Impact factor: 4.030

View more
  9 in total

Review 1.  Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.

Authors:  Sulpicio G Soriano; J A Jeevendra Martyn
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 3.  Clinical pharmacology of the perinatal period and early infancy.

Authors:  P L Morselli
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

4.  Biointeraction analysis of carbamazepine binding to alpha1-acid glycoprotein by high-performance affinity chromatography.

Authors:  Hai Xuan; K S Joseph; Chunling Wa; David S Hage
Journal:  J Sep Sci       Date:  2010-08       Impact factor: 3.645

5.  In vivo binding characteristics of carbamazepine and carbamazepine-10,11-epoxide to serum proteins in paediatric patients with epilepsy.

Authors:  Y Kodama; K Tsutsumi; M Kuranari; H Kodama; I Fujii; M Takeyama
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration.

Authors:  A Baruzzi; M Contin; E Perucca; F Albani; R Riva
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

9.  Plasma protein binding of risperidone and its distribution in blood.

Authors:  G Mannens; W Meuldermans; E Snoeck; J Heykants
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.